HIV infection and compromised mucosal immunity: Oral manifestations and systemic inflammation

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Heron, Samantha E ^a   Elahi, Shokrollah ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

HIV; Immune activation; Immunosenescence; Mucosal immunity; Oral mucosa; Periodontal disease

Indexed keywords

BETA DEFENSIN; CATHELICIDIN; CD15 ANTIGEN; CD16 ANTIGEN; CYTOKINE; DEFENSIN; HISTATIN; IMMUNOGLOBULIN A; LACTOFERRIN; LYSOZYME; MONOCYTE CHEMOTACTIC PROTEIN; PROTEINASE; TUMOR NECROSIS FACTOR;

ANTIRETROVIRAL THERAPY; CELL REGENERATION; CHEILITIS; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSENESCENCE; INFLAMMATION; INNATE IMMUNITY; MICROBIOME; MOUTH CAVITY; MOUTH FLORA; MUCOSAL IMMUNITY; NONHUMAN; OROPHARYNX CANDIDIASIS; PATTERN RECOGNITION; PERIODONTAL DISEASE; PREVALENCE; REVIEW; SALIVA; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 85017238374     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00241     Document Type: Review

References (201)

1. GARPR. UNAIDS 2016 Estimates. Global AIDS Response Progress Reporting. (2016). Available from: https://aidsreportingtool.unaids.org/static/docs/GARPR_Guidelines_2016_EN.pdf
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med (1998) 338(13):853-60. doi:10.1056/NEJM199803263381301
3. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease, time for a better understanding. J Am Coll Cardiol (2013) 61:511-23. doi:10.1016/j.jacc.2012.06.063
4. Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS (2016) 30:171-83. doi:10.1097/QAD.0000000000000917
5. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 53(11):1120-6. doi:10.1093/cid/cir627
6. Leng SX, Margolick JB. Understanding frailty, aging, and inflammation in HIV infection. Curr HIV/AIDS Rep (2015) 12(1):25-32. doi:10.1007/s11904-014-0247-3
7. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone (2006) 38(6):893-7. doi:10.1016/j.bone.2005.11.001
8. Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis (2015) 212:1563-73. doi:10.1093/infdis/jiv277
9. Nasi M, Pinti M, De Biasi S, Gibellini L, Ferraro D, Mussini C, et al. Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett (2014) 162(1):329-33. doi:10.1016/j.imlet.2014.06.012
10. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med (2012) 20:101-5.
11. Sankaran S, Guadalupe M, Reay E, George MD, Flamm J, Prindiville T, et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A (2005) 102(28):9860-5. doi:10.1073/pnas.0503463102
12. Nilsson J, Kinloch-de-Loes S, Granath A, Sonnerborg A, Goh L, Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS (2007) 21:565-74. doi:10.1097/QAD.0b013e3280117204
13. Kim CJ, McKinnon LR, Kovacs CM, Kandel G, Huibner S, Chege D, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol (2013) 191(5):2164-73. doi:10.4049/jimmunol.1300829
14. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 254(1):326-42. doi:10.1111/imr.12065
15. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS (2008) 3(3):356-61. doi:10.1097/COH.0b013e3282f9ae9c
16. Wu RQ, Zhang ZF, Tu E, Chen QM, Chen W. The mucosal immune system in the oral cavity-an orchestra of T cell diversity. Int J Oral Sci (2014) 6:125-32. doi:10.1038/ijos.2014.48
17. McClure R, Massari P. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol (2014) 5:386. doi:10.3389/fimmu.2014.00386
18. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med (2008) 23:2079-86. doi:10.1007/s11606-008-0787-6
19. Leishman SJ, Do HL, Ford PJ. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol (2010) 2(10):5781-94. doi:10.3402/jom.v2i0.5781
20. Dhadse P, Gattani D, Mishra R. The link between periodontal disease and cardiovascular disease: how far we have come in last two decades? J Indian Soc Periodontol (2010) 14(3):148-54. doi:10.4103/0972-124X.75908
21. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ; CDC Periodontal Disease Surveillance Workgroup: James Beck (University of North Carolina, Chapel Hill, USA), et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res (2012) 91(10):914-20. doi:10.1177/0022034512457373
22. Holmstrup P, Glick M. Treatment of periodontal disease in the immunodeficient patient. Periodontol (2000) 28(2002):190-205. doi:10.1034/j.1600-0757.2002.280108.x
23. Li Y, Saxena D, Chen Z, Liu G, Abrams WR, Phelan JA, et al. HIV infection and microbial diversity in saliva. J Clin Microbiol (2014) 52(5):1400-11. doi:10.1128/JCM.02954-13
24. Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV? AIDS (2010) 24(1):5-16. doi:10.1097/QAD.0b013e328333525f
25. Vaseliu N, Kamiru HN, Kabue M. Oral manifestations of HIV infection. Contemp Clin Dent (2010) 1:1-5. doi:10.4103/0976-237X.62510
26. Feller L, Altini M, Khammissa RA, Chandran R, Bouckaert M, Lemmer J. Oral mucosal immunity. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 116:576-83. doi:10.1016/j.oooo.2013.07.013
27. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med (2008) 14(5):191-8. doi:10.1016/j.molmed.2008.03.001
28. Nittayananta W, Tao R, Jiang L, Peng Y, Huang Y. Oral innate immunity in HIV infection in HAART era. J Oral Pathol Med (2016) 45:3-8. doi:10.1111/jop.12304
29. Hovav AH. Dendritic cells of the oral mucosa. Mucosal Immunol (2014) 7(1):27-37. doi:10.1038/mi.2013.42
30. Fabian TK, Hermann P, Beck A, Fejerdy P, Favian G. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int J Mol Sci (2012) 13(4):4295-320. doi:10.3390/ijms13044295
31. Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev (2013) 26(4):781-91. doi:10.1128/CMR.00021-13
32. Schulz BL, Cooper-White J, Punyadeera CK. Saliva proteome research: current status and future outlook. Crit Rev Biotechnol (2012) 33:246-59. doi:10.3109/07388551.2012.687361
33. Kawas SA, Rahim ZH, Ferguson DB. Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol (2012) 57:1-9. doi:10.1016/j.archoralbio.2011.06.013
34. Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol (2005) 7(2):119-33.
35. Iwasaki M, Yoshihari A, Hirotomi T, Ogawa H, Hanada N, Miyazaki H. Longitudinal study on the relationship between serum albumin and periodontal disease. J Clin Periodontol (2008) 35(4):291-6. doi:10.1111/j.1600-051X.2008.01215.x
36. Walker DM. Oral mucosal immunology: an overview. Ann Acad Med Singapore (2004) 33:27S-30S.
37. Czerkinsky C, Anjuere F, McGhee JR, George-Changy A, Holmgren J, Kieny MP, et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev (1999) 170:197-222. doi:10.1111/j.1600-065X.1999.tb01339.x
38. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol (2013) 5:20401-25. doi:10.3402/jom.v5i0.20401
39. Diamond G, Beckloff N, Ryan LK. Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res (2008) 87(10):915-27. doi:10.1177/154405910808701011
40. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun (2005) 73(3):1271-4. doi:10.1128/IAI.73.3.1271-1274.2005
41. Wong JH, Legowska A, Rolka K, Ng TB, Hui M, Cho CH, et al. Effects of cathelicidin and its fragments on three key enzymes of HIV-1. Peptides (2011) 32(6):1117-22. doi:10.1016/j.peptides.2011.04.017
42. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J Invest Dermatol (2001) 117:91-7. doi:10.1046/j.1523-1747.2001.01340.x
43. Murakami M, Ohtake T, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res (2002) 81:845-50. doi:10.1177/154405910208101210
44. Chang TL, Klotman ME. Defensins: natural anti-HIV peptides. AIDS (2004) 6:161-8.
45. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial B-defensins 2 and 3 inhibit HIV-1 replication. AIDS (2003) 17:F39-48. doi:10.1097/00002030-200311070-00001
46. Khurshid Z, Naseem M, Sheikh Z, Najeeb S, Shahab S, Zafar MS. Oral antimicrobial peptides: types and roles in the oral cavity. Saudi Pharm J (2016) 24(5):515-24. doi:10.1016/j.jsps.2015.02.015
47. Berlutti F, Pilloni A, Pietropaoli M, Polimeni A, Valenti P. Lactoferrin and oral diseases: current status and perspective in periodontitis. Ann Stomatol (2011) 2(3-4):10-8.
48. Lin AL, Johnson DA, Patterson TF, Wu Y, Lu DL, Shi Q, et al. Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol (2001) 16:270-8. doi:10.1034/j.1399-302x.2001.016005270.x
49. Shine N, Konopka K, Duzgunes N. The anti-HIV-1 activity associated with saliva. J Dent Res (1997) 76(2):634-40. doi:10.1177/00220345970760020301
50. Edgerton M, Koshlukova SE. Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv Dent Res (2000) 14:16-21. doi:10.1177/08959374000140010201
51. Jentsch H, Sievert Y, Gocke R. Lactoferrin and other markers from gingival crevicular fluid and saliva before and after periodontal treatment. J Clin Periodontol (2004) 31:511-4. doi:10.1111/j.1600-051X.2004.00512.x
52. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol (2005) 79:6432-40. doi:10.1128/JVI.79.10.6432-6440.2005
53. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 96:456-64. doi:10.1172/JCI118056
54. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, et al. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis (1997) 3:S64-9. doi:10.1111/j.1601-0825.1997.tb00377.x
55. Miller CS, Foley JD, Bailey AL, Campbell CL, Humphries RL, Christodoulides N, et al. Current developments in salivary diagnostics. Biomark Med (2010) 4(1):171-89. doi:10.2217/bmm.09.68
56. Schipper R, Loof A, de Groot J, Harthoorn L, Dransfield E, van Heerde W. SELDI-TOF-MS of saliva: methodology and pre-treatment effects. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 847:45-53. doi:10.1016/j.jchromb.2006.10.005
57. Ng PY, Donley M, Hausmann E, Hutson AD, Rossomando EF, Scannapieco FA. Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies. FEMS Immunol Med Microbiol (2007) 49(2):252-60. doi:10.1111/j.1574-695X.2006.00187.x
58. Fine DH, Markowitz K, Fairlie K, Tischio-Bereski D, Ferrandiz J, Godboley D, et al. Macrophage inflammatory protein-1a shows predictive value as a risk marker for subjects and sits vulnerable to bone loss in a longitudinal model of aggressive periodontitis. PLoS One (2014) 9(6):e98541. doi:10.1371/journal.pone.0098541
59. Goodsell DS. The molecular perspective: tumor necrosis factor. Oncologist (2006) 11(1):83-4. doi:10.1634/theoncologist.11-7-849
60. Elahi S, Pang G, Ashman RB, Clancy R. Nitric oxide-enhanced resistance to oral candidiasis. Immunology (2001) 104:447-54. doi:10.1046/j.1365-2567.2001.01331.x
61. Joel TJ, Suguna S, Steffi SR. Antimicrobial activity of lysozyme against oral pathogens. Asian J Pharm Res Health Care (2016) 8(2):42-6. doi:10.18311/ajprhc/2016/662
62. Sato EJ, Choudhury T, Nishikawa T, Inoue M. Dynamic aspect of reactive oxygen and nitric oxide in oral cavity. J Clin Biochem Nutr (2008) 42:8-13. doi:10.3164/jcbn.2008002
63. Bastos MF, Lima JA, Vieira PM, Mestnik MJ, Faveri M, Duarte PM. TNF-alpha and IL-4 levels in generalized aggressive periodontitis subjects. Oral Dis (2009) 15:82-7. doi:10.1111/j.1601-0825.2008.01491.x
64. Miller CS, King CP, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc (2006) 137(3):322-9. doi:10.14219/jada.archive.2006.0181
65. Noh MK, Jung M, Kim SH, Lee SR, Park KH, Kim DH, et al. Assessment of IL-6, IL-8 and TNF-α levels in the gingival tissue of patients with periodontitis. Exp Ther Med (2013) 6(3):847-51. doi:10.3892/etm.2013.1222
66. Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1B levels and periodontal clinical status. Arch Oral Biol (2008) 53(4):346-52. doi:10.1016/j.archoralbio.2007.11.005
67. Botero JE, Contreras A, Parra B. Profiling of inflammatory cytokines produced by gingival fibroblasts after human cytomegalovirus. Oral Microbiol Immunol (2008) 23:291-8. doi:10.1111/j.1399-302X.2007.00427.x
68. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 91(4):521-30. doi:10.1016/S0092-8674(00)80438-9
69. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol (2000) 164(6):3368-76. doi:10.4049/jimmunol.164.6.3368
70. Tremblay K, Lemire M, Provost V, Pastinen T, Renaud Y, Sandord AJ, et al. Association study between the CX3CR1 gene and asthma. Genes Immun (2006) 7(8):632-9. doi:10.1038/sj.gene.6364340
71. Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Atk. Arthritis Rheum (2007) 56:2512-22. doi:10.1002/art.22806
72. Hosokawa Y, Nakanishi T, Yamaguchi D, Nakae H, Matsuo T. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Clin Exp Immunol (2005) 139:506-12. doi:10.1111/j.1365-2249.2005.02675.x
73. Jonsson D, Amisten S, Bratthall G, Holm A, Nilsson BO. LPS induces GROa chemokine production via NF-kB in oral fibroblasts. Inflamm Res (2009) 58:791-6. doi:10.1007/s00011-009-0049-z
74. Almasri A, Wisithphrom K, Windsor LJ, Olson B. Nicotine and lipopolysaccharide affect cytokine expression from gingival fibroblasts. J Periodontol (2007) 78:533-41. doi:10.1902/jop.2007.060296
75. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest (1991) 88:1121-7. doi:10.1172/JCI115411
76. Pradeep AR, Daisy H, Hadge P. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 in periodontal health and disease. Arch Oral Biol (2009) 54(5):503-9. doi:10.1016/j.archoralbio.2009.02.007
77. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol (1992) 149:722-7.
78. Yu X, Barnhill RT, Graves DT. Expression of monocyte chemoattractant protein-1 (MCP-1) in delayed type hypersensitivity reactions in the skin. Lab Invest (1994) 71:235-66.
79. Yu XH, Antoniades H, Graves DT. Expression of monocyte-chemoattractant protein-1 in human inflamed gingival tissues. Infect Immun (1993) 61:4622-8.
80. Ozaki K, Hanazawa S, Takeshita A, Chen Y, Watanabe A, Nishida K, et al. Interleukin-1B and tumor necrosis factor-alpha stimulate synergistically the expression of monocyte chemoattractant protein-1 in fibroblastic cells derived from human periodontal ligament. Oral Microbiol Immunol (1996) 11(2):109-14. doi:10.1111/j.1399-302X.1996.tb00344.x
81. Ram VS, Parthiban, Sudhakar U, Mithradas N, Prabhakar R. Bone biomarkers in periodontal disease: a review article. J Clin Diagn Res (2015) 9(1):ZE07-10. doi:10.7860/JCDR/2015/11268.5438
82. Hanazawa S, Kawata Y, Takeshita A, Kumada H, Okithu M, Tanaka S, et al. Expression of monocyte chemoattractant protein 1 (MCP-1) in adult periodontal disease: increased monocyte chemotactic activity in crevicular fluids and induction of MCP-1 expression in gingival tissues. Infect Immun (1993) 6(12):5219-24.
83. Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1a (MIP-1a) in multiple myeloma. Leuk Lymphoma (2005) 46(12):1699-707. doi:10.1080/10428190500175049
84. Thomadaki K, Helmerhorst EJ, Tian N, Sun X, Siqueira WL, Walt DR, et al. Whole-saliva proteolysis and its impact on salivary diagnostics. J Dent Res (2011) 90(11):1325-30. doi:10.1177/0022034511420721
85. Esser D, Alvarez-Llamas G, de Vries MP, Weening D, Vonk RJ, Roelofsen H. Sample stability and protein composition of saliva. Implications for its use as a diagnostic fluid. Biomark Insights (2008) 3:25-37.
86. Vastardis S, Leigh JE, Wozniak K, Yukna R, Fidel PL. Influence of periodontal disease on Th1/Th2-type cytokines in saliva of HIV-positive individuals. Oral Microbiol Immunol (2003) 18:88-91. doi:10.1034/j.1399-302X.2003.00045.x
87. Holt SC, Ebersole JL. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. Periodontol (2000) 2005(38):72-122. doi:10.1111/j.1600-0757.2005.00113.x
88. Abu Eid R, Sawair F, Landini G, Saku T. Age and the architecture of oral mucosa. Age (2012) 34(3):651-8. doi:10.1007/s11357-011-9261-1
89. Bodineau A, Coulomb B, Tedesco AC, Seguier S. Increase of gingival matured dendritic cells number in elderly patients with chronic periodontitis. Arch Oral Biol (2009) 54:12-6. doi:10.1016/j.archoralbio.2008.06.014
90. Boehm TK, Scannapieco FA. The epidemiology, consequences and management of periodontal disease in older adults. J Am Dent Assoc (2007) 138(9):S26-33. doi:10.14219/jada.archive.2007.0360
91. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res (2006) 19:29-35. doi:10.1177/154407370601900107
92. Nittayananta W, Mitarnun W, Talungchit S, Sriplung H. Changes in oral cytokeratin expression in HIV-infected subjects with long-term use of HAART. Oral Dis (2012) 18(8):793-801. doi:10.1111/j.1601-0825.2012.01947.x
93. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis (1998) 178(6):1635-41. doi:10.1086/314511
94. Nittayananta W, Kemapunmanus M, Yangngam S, Talungchit S, Sriplung H. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med (2013) 42(3):208-15. doi:10.1111/jop.12023
95. Shugars DC, Sweet SP, Malamud D, Kazmi SH, Page-Shafer K, Challacombe SJ. Saliva and inhibition of HIV-1 infection: molecular mechanisms. Oral Dis (2002) 8(2):169-75. doi:10.1034/j.1601-0825.8.s2.7.x
96. Wang G, Watson KM, Buckheit RW Jr. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother (2008) 52:3438-40. doi:10.1128/AAC.00452-08
97. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol (2006) 13(10):1111-8. doi:10.1128/CDLI.00426-05
98. Veerman EC, van den Keybus PA, Vissink A, Nieuw Amerongen AV. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci (1996) 104:346-52. doi:10.1111/j.1600-0722.1996.tb00090.x
99. Lee-Huang S, Huang PL, Sun Y, Huang PL, Kung H, Blithe DL, et al. Lysozyme and RNases as anti-HIV components in B-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci U S A (1999) 96(6):2678-81. doi:10.1073/pnas.96.6.2678
100. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leucocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 90:1141-9.
101. Hienz SA, Paliwal S, Ivanovski S. Mechanisms of bone resorption in periodontitis. J Immunol Res (2014) 2015(2014):1-11. doi:10.1155/2015/615486
102. Franchi L, Warner N, Viani K, Nunez G. Function of NOD-like receptors in microbial recognition and host defense. Immunol Rev (2010) 227(1):106-28. doi:10.1111/j.1600-065X.2008.00734.x
103. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. NOD-like proteins in immunity, inflammation and disease. Nat Immunol (2006) 7(12):1250-7. doi:10.1038/ni1412
104. Kufer TA, Banks DJ, Philpott DJ. Innate immune sensing of microbes by NOD proteins. Ann N Y Acad Sci (2006) 1072:19-27. doi:10.1196/annals.1326.020
105. Uehara A, Takada H. Synergism between TLRs and NOD1/2 in oral epithelial cells. J Dent Res (2008) 87(7):682-6. doi:10.1177/154405910808700709
106. Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol (2007) 44:3100-11. doi:10.1016/j.molimm.2007.02.007
107. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: a prospective study and updated meta-analyses. BMJ (2000) 321:199-204. doi:10.1136/bmj.321.7255.199
108. Zakynnthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. Int J Cardiol (2009) 53(3):317-33. doi:10.1016/j.jjcc.2008.12.007
109. Dang AT, Cotton S, Sankaran-Walters S, Li C-S, Lee C-YM, Dandekar S, et al. Evidence of an increased pathogenic footprint in the lingual microbiome of untreated HIV infected patients. BMC Microbiol (2012) 12:153. doi:10.1186/1471-2180-12-153
110. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis (2012) 55:126-36. doi:10.1093/cid/cis406
111. Egusa H, Nikawa H, Makihira S, Yatani H, Hamada T. In vitro mechanisms of interleukin-8-mediated responses of human gingival epithelial cells to Candida albicans infection. Int J Med Microbiol (2006) 296(4-5):301-11. doi:10.1016/j.ijmm.2005.12.017
112. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 102(3):318-24. doi:10.1016/j.tripleo.2005.07.021
113. Muller F, Holberg-Petersen M, Rollag H, Degre M, Brandtzaeg P, Froland SS. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr (1992) 5(1):46-51.
114. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology (2013) 140:22-30. doi:10.1111/imm.12117
115. Zavala WD, Cavicchia JC. Deterioration of the Langerhans cell network of the human gingival epithelium with aging. Arch Oral Biol (2006) 51:1150-5. doi:10.1016/j.archoralbio.2006.06.008
116. Lukic A, Vasilijic S, Majstorovic I, Vucevic D, Mojsilovic S, Gazivoda D, et al. Characterization of antigen-presenting cells in human apical periodontitis lesions by flow cytometry and immunocytochemistry. Int Endod J (2006) 39:626-36. doi:10.1111/j.1365-2591.2006.01125.x
117. Al-Sabbagh M, Alladah A, Lin Y, Kryscio RJ, Thomas MD, Ebersole JL, et al. Bone remodeling-associated salivary biomarker MIP-1a distinguishes periodontal disease from health. J Periodontal Res (2012) 47:389-95. doi:10.1111/j.1600-0765.2011.01445.x
118. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood (2010) 116:e74-80. doi:10.1182/blood-2010-02-258558
119. Boltjes A, van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol (2014) 5:131. doi:10.3389/fimmu.2014.00131
120. Ali A, Rautemaa R, Hietanen J, Beklen A, Konttinen Y. A possible CD1a Langerhans cell-mast cell interaction in chronic hyperplastic candidosis. J Oral Pathol Med (2007) 36(6):329-36. doi:10.1111/j.1600-0714.2007.00527.x
121. Dutzan N, Konkel JE, Greenwell-Wild T, Moutsopoulos NM. Characterization of the human immune cell network at the gingival barrier. Mucosal Immunol (2016) 9(5):1163-72. doi:10.1038/mi.2015.136
122. Elahi S, Pang G, Clancy R, Ashman RB. Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect Immun (2000) 68(10):5771-7. doi:10.1128/IAI.68.10.5771-5777.2000
123. Cortes-Vieyra R, Rosales C, Uribe-Querol E. Neutrophil functions in periodontal homeostasis. J Immunol Res (2016) 2016:1396106. doi:10.1155/2016/1396106
124. Eskan MA, Jotwani R, Abe T, Chmelar J, Lim JH, Liang S, et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol (2012) 13(5):465-73. doi:10.1038/ni.2260
125. Fujihashi K, Yamamoto M, Hiroi T, Bamberg TV, McGhee JR, Kiyoni H. Selected Th1 and Th2 cytokine mRNA expression by CD4+ T cells isolated from inflamed human gingival tissues. Clin Exp Immunol (1996) 103:422-8. doi:10.1111/j.1365-2249.1996.tb08297.x
126. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med (2001) 12(2):125-35. doi:10.1177/10454411010120020301
127. Takeichi O, Haber J, Kawai T, Smith DJ, Moro I, Taubman MA. Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. J Dent Res (2000) 79(8):1548-55. doi:10.1177/00220345000790080401
128. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol (2008) 79:1569-76. doi:10.1902/jop.2008.080233
129. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol (2002) 14(1):103-10. doi:10.1016/S0952-7915(01)00304-1
130. Muthukuru M, Jotwani R, Cutler CW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun (2005) 73(2):687-94. doi:10.1128/IAI.73.2.687-694.2005
131. Sugawara Y, Uehara A, Fujimoto Y, Kusomoto S, Fuakse K, Shibata K, et al. Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res (2006) 85(6):524-9. doi:10.1177/154405910608500609
132. Uehara A, Sugawara Y, Tamai R, Takada H. Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD14. Med Microbiol Immunol (2001) 189:185-92. doi:10.1007/s004300100063
133. Mori Y, Yoshimuri A, Ukai T, Lien E, Espevik T, Hara Y. Immunohistochemical localization of toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Microbiol Immunol (2003) 18(1):54-8. doi:10.1034/j.1399-302X.2003.180109.x
134. Takeda K, Akira S. Microbial recognition by toll-like receptors. J Dermatol Sci (2004) 34:73-82. doi:10.1016/j.jdermsci.2003.10.002
135. Nussbaum G, Ben-Adi S, Genzier T, Sela M, Rosen G. Involvement of toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun (2009) 77(9):3939-47. doi:10.1128/IAI.00488-09
136. Oviedo-Boyso J, Bravo-Patino A, Baizabal-Aguirre VM. Collaborative action of toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. Mediators Inflamm (2014) 2014:432785. doi:10.1155/2014/432785
137. Moutsopoulos NM, Greenwell-Wild T, Wahl SM. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res (2006) 19:52-6. doi:10.1177/154407370601900111
138. Cervantes CA, Oliveira LM, Manfrere KC, Lima JF, Pereira NZ, Duarte AJ. Antiviral factors and type I/III interferon expression associated with regulatory factors in the oral epithelial cells from HIV-1 serodiscordant couples. Sci Rep (2016) 6:1-8. doi:10.1038/srep25875
139. Baggaley RF, White RG, Boily MC. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol (2008) 37:1255-65. doi:10.1093/ije/dyn151
140. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 39(4):1048-63. doi:10.1093/ije/dyq057
141. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS (2006) 20(6):805-12. doi:10.1097/01.aids.0000218543.46963.6d
142. Wood LF, Charoudi A, Chen HL, Jaspan HB, Sodora DL. The oral mucosa immune environment and oral transmission of HIV/SIV. Immunol Rev (2013) 254(1):1-34. doi:10.1111/imr.12078
143. Truong HH, Berrey MM, Shea T, Diem K, Corey L. Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. J Acquir Immune Defic Syndr (2002) 29:232-43.
144. del Romero J, Marinovich B, Castilla J, Garcia S, Campo J, Hernando V, et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS (2002) 16(9):1296-7. doi:10.1097/00002030-200206140-00017
145. Campo J, Perea MA, Romero JD, Cano J, Hernando V, Bascones A. Oral transmission of HIV, reality or fiction? An update. Oral Dis (2006) 12:219-28. doi:10.1111/j.1601-0825.2005.01187.x
146. Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr (1996) 13(1):87-92. doi:10.1097/00042560-199609000-00012
147. Wallace JI, Porter J, Weiner A, Steinberg A. Oral sex, crack smoking, and HIV infection among female sex workers who do not inject drugs. Am J Public Health (1997) 87(3):470. doi:10.2105/AJPH.87.3.470
148. Baron S, Poast J, Cloyd MW. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med (1999) 159:303-10. doi:10.1001/archinte.159.3.303
149. Gaillard P, Verhofstede C, Mwanyumba F, Claeys P, Chohan V, Mandaliya K, et al. Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS (2000) 14(15):2341-8. doi:10.1097/00002030-200010200-00015
150. John-Stewart G. Infant feeding and prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS (2008) 3:173-9. doi:10.1097/COH.0b013e3282f50bc6
151. Kamiru HN, Naidoo S. Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ (2002) 57(11):479-82.
152. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis (2002) 8(2):98-109. doi:10.1034/j.1601-0825.2002.00020.x
153. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effects of highly active antiretroviral therapy on frequency of oral warts. Lancet (2001) 357:1411-2. doi:10.1016/S0140-6736(00)04578-5
154. Moodley A, Wood NH. HIV-associated oral lesions in HIV-seropositive patients at an HIV-treatment clinic in South Africa. J AIDS Clin Res (2015) 6:422. doi:10.4172/2155-6113.1000422
155. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol (2013) 8:477-512. doi:10.1146/annurev-pathol-011110-130318
156. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 25:821-52. doi:10.1146/annurev.immunol.25.022106.141557
157. Huppler AR, Conti HR, Hernandez-Santos N, Darville T, Biswas PS, Gaffen SL. Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis. J Immunol (2014) 192(4):1745-52. doi:10.4049/jimmunol.1302265
158. Ullmann BD, Myers H, Chiranand W, Lazzell AL, Zhao Q, Vega LA, et al. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell (2004) 3(3):715-23. doi:10.1128/EC.3.3.715-723.2004
159. Taiwo OO, Hassan Z. The impact of highly active antiretroviral therapy (HAART) on the clinical features of HIV-related oral lesions in Nigeria. AIDS Res Ther (2010) 7:19-25. doi:10.1186/1742-6405-7-19
160. Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis (2002) 185(2):188-95. doi:10.1086/338445
161. De Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schafer W, et al. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis (1999) 179(1):201-8. doi:10.1086/314546
162. Bodhade AS, Ganvir SM, Hazarey VK. Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci (2011) 53(2):203-11. doi:10.2334/josnusd.53.203
163. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis (2002) 6:152-7. doi:10.1111/j.1601-0825.2000.tb00326.x
164. Beachler DC, D'Souza G. Oral HPV infection and head and neck cancers in HIV-infected individuals. Curr Opin Oncol (2013) 25(5):503-10. doi:10.1097/CCO.0b013e32836242b4
165. Hille JJ, Webster-Cyriaque J, Palefski JM, Raab-Traub N. Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Dis (2002) 8(s2):161-8. doi:10.1034/j.1601-0825.2002.00028.x
166. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 97(6):425-32. doi:10.1093/jnci/dji072
167. Mukherjee PK, Chandra J, Retuerto M, Sikaroodi M, Brown RE, Jurevic R, et al. Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog (2014) 10(3):e1003996. doi:10.1371/journal.ppat.1003996
168. Kistler JO, Arirachakaran P, Poovorawan Y, Dahlen G, Wade WG. The oral microbiome in human immunodeficiency virus (HIV)-positive individuals. J Med Microbiol (2015) 64:1094-101. doi:10.1099/jmm.0.000128
169. Moyes DL, Saxena D, John MD, Malamud D. The gut and oral microbiome in HIV disease: a workshop report. Oral Dis (2016) 22(Suppl 1):166-70. doi:10.1111/odi.12415
170. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation (1999) 100(4):e20-8. doi:10.1161/01.CIR.100.4.e20
171. Mejer N, Gotland N, Uhre ML, Westh H, Schonheyder HC, Petersen A, et al. Increased risk of arterial thromboembolic events after Staphylococcus aureus bacteremia: a matched cohort study. J Infect Dis (2015) 71(2):167-78. doi:10.1016/j.jinf.2015.03.010
172. Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases: paradigm of periodontal infections. Ann N Y Acad Sci (2006) 1088:251-64. doi:10.1196/annals.1366.032
173. Petersen PE, Ogawa H. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol (2012) 60:15-39. doi:10.1111/j.1600-0757.2011.00425.x
174. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ (2005) 83:700-6.
175. Palmer GD, Robinson PG, Challacombe SJ, Birnbaum W, Croser D, Erridge PL, et al. Aetiological factors for oral manifestations of HIV infection. Oral Dis (1996) 2:193-7. doi:10.1111/j.1601-0825.1996.tb00223.x
176. Li X, Kollveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev (2000) 13(4):547-58. doi:10.1128/CMR.13.4.547-558.2000
177. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol (2000) 71(10):1554-60. doi:10.1902/jop.2000.71.10.1554
178. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem (1997) 43:52-8.
179. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationship between periodontal disease and C-reactive protein among adults in the atherosclerosis risk in communities study. JAMA (2003) 163(10):1172-9. doi:10.1001/archinte.163.10.1172
180. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci (2011) 48(4):155-70. doi:10.3109/10408363.2011.599831
181. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol (2001) 72(9):1221-7. doi:10.1902/jop.2000.72.9.1221
182. Ardila CM, Guzman IC. Comparison of serum amyloid A protein and C-reactive protein levels as inflammatory markers in periodontitis. J Periodontal Implant Sci (2015) 45(1):14-22. doi:10.5051/jpis.2015.45.1.14
183. Walford RL. The immunologic theory of aging. Gerontologist (1964) 4(4):195-7. doi:10.1093/geront/4.4.195
184. Pommier J-P, Gauthier L, Livartowski J, Galanaud P, Boue F, Dulioust A, et al. Immunosenescence in HIV pathogenesis. Virology (1997) 231:148-54. doi:10.1006/viro.1997.8512
185. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 7:4-10. doi:10.1007/s11904-009-0038-4
186. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice A. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol (2012) 24(5):506-16. doi:10.1097/CCO.0b013e328355e131
187. Lohse N, Hansen AE, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 146:87-95. doi:10.7326/0003-4819-146-2-200701160-00003
188. Manfredi R. HIV disease and advanced age. An increasing therapeutic challenge. Drugs Aging (2002) 19(9):647-69. doi:10.2165/00002512-200219090-00003
189. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 62:141-55. doi:10.1146/annurev-med-042909-093756
190. Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, et al. T cell ageing: effects of age on development, survival and function. Indian J Med Res (2013) 138:595-608.
191. Okoye AA, Picker LJ. CD4+ T cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2014) 254(1):54-64. doi:10.1111/imr.12066
192. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 200:761-70. doi:10.1084/jem.20041196
193. Fevrier M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency (HIV) infection: role of apoptosis. Viruses (2011) 3(5):586-612. doi:10.3390/v3050586
194. Nannini EC, Okhuysen PC. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr Gastroenterol Rep (2002) 4(5):392-8. doi:10.1007/s11894-002-0009-z
195. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 12(12):1365-71. doi:10.1038/nm1511
196. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol (2008) 214:231-41. doi:10.1002/path.2276
197. Ryan ES, Micci L, Fromentin R, Paganini S, McGary CS, Easley K, et al. Loss of function of intestinal IL-17 and IL-22 producing cells contributes to inflammation and viral persistence in SIV-infected rhesus macaques. PLoS Pathog (2016) 12(2):e1005412. doi:10.1371/journal.ppat.1005412
198. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JM, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2009) 457:722-5. doi:10.1038/nature07537
199. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol (2013) 13:75-87. doi:10.1038/nri3349
200. Kloverpris HN, Kazer SW, Mjosberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. Innate lymphoid cells are depleted irreversible during acute HIV-1 infection in the absence of viral suppression. Immunity (2016) 44:391-405. doi:10.1016/j.immuni.2016.01.006
201. Genovese L, Nebuloni M, Alfano M. Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol (2013) 4:86. doi:10.3389/fimmu.2013.00086